Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO TEST FINALE: continuation versus cessation of urate-lowering therapy in gout remission
NL-OMON52436Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of allopurinol, benzbromarone and febuxostat in gout (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Proportion maintaining adapted gout remission at 24 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
allopurinolbenzbromaronefebuxostat
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON52436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52436.